Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $6.64 Consensus Target Price from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have received an average rating of "Hold" from the twelve brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.64.

A number of research firms have recently issued reports on MRVI. Morgan Stanley cut their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 25th. UBS Group cut their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a report on Friday, March 21st. Robert W. Baird decreased their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Craig Hallum dropped their price objective on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Stifel Nicolaus set a $5.00 target price on shares of Maravai LifeSciences in a report on Friday, March 21st.

Maravai LifeSciences Stock Up 6.2%

Shares of MRVI stock traded up $0.16 during trading on Friday, reaching $2.76. The company's stock had a trading volume of 2,461,569 shares, compared to its average volume of 2,290,926. Maravai LifeSciences has a one year low of $1.67 and a one year high of $10.03. The business has a fifty day moving average price of $2.24 and a 200-day moving average price of $3.14. The company has a market cap of $702.86 million, a price-to-earnings ratio of -2.42 and a beta of 0.28. The company has a quick ratio of 5.17, a current ratio of 5.96 and a debt-to-equity ratio of 0.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The company's revenue was down 26.9% compared to the same quarter last year. Analysts anticipate that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Performa Ltd US LLC lifted its position in shares of Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after acquiring an additional 4,300 shares during the period. Farther Finance Advisors LLC lifted its position in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after purchasing an additional 9,916 shares during the period. Cibc World Markets Corp acquired a new stake in Maravai LifeSciences during the fourth quarter worth about $56,000. Atria Investments Inc acquired a new stake in Maravai LifeSciences during the fourth quarter worth about $58,000. Finally, McAdam LLC bought a new position in Maravai LifeSciences in the 1st quarter valued at about $31,000. 50.25% of the stock is owned by institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.